Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), on Wednesday agreed to acquire Emalex Biosciences, including its lead asset, ecopipam.
Teva To Acquire Emalex, Expanding Late-Stage Pipeline
Teva will pay $700 million, and Emalex’s shareholders will be eligible to receive up to $200 million based on future commercial milestones and royalties on global net sales of ecopipam, subject to regulatory approval.
“This is a prime example of our Pivot to Growth strategy in action, advancing focused, capital-efficient agreements that expand our late-stage innovative pipeline and commercial portfolio,” said Teva CEO Richard Francis.
The transaction is currently anticipated to close by the third quarter of 2026.
Teva will fund the upfront payment using cash on hand. The company intends to mitigate the near-term margin dilutive impact of this acquisition and remains on track to meet its 2027 financial targets.
data-variant=”card”
data-news-mode=”manual”
>
Read Also: